Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Myelofibrosis: LSD1 INHIBITOR IMG-7289

Kristen Pettit • 15 Jun 2019
EHA 2019
Myelofibrosis IMG-7289

Kristen Pettit, MD, University of Michigan, Ann Arbor, MI, tells us about the use of the LSD1 INHIBITOR IMG-7289 in the treatment of myelofibrosis. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Kristen Pettit

1:02
Myelofibrosis: unmet needs
Kristen Pettit • 14 Jun 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals